RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Vera gone??..
stocksnbonds458 wrote: With all due respect Enrique, in her own words she was there to bring this to commercialization. Per Vera: "I feel my extensive global experience in clinical research and quality assurance will support the Companys primary objective of successfully developing with the objective of commercializing its Anti-Cancer Therapy (ACT) technology". At the very least, IMHO, the shareholders deserve an explanation of her departure and not just a quickie one liner couched within a parapraph in the recent update. Theralase is not treating its shareholders with respect here.
In addition to cost savings, considering our new fully equipped research center (effective 4/2022) & recent association with LKSKI, I imagine there was also a fair degree of duplication/overlap in expertise with respect to clinical trial guidance & commercialization. Nonetheless, I feel confident TLT benefited from whatever additional info/value she was able to provide (in conjunction with LKSKI) during her limited employment...planned or unplanned. JMO.